James White, CEO and Owner KBMO Diagnostics

Over 20 years of Diagnostic and Pharmaceutical experience working globally launching a range of innovative products to help with cardiovascular disease ranging from multiplex molecular diagnostic instruments and assays thru to Point of Care blood gas solutions.
James acquired the developer of the patented FIT (Food Inflammation Test) Test which is the first assay to identify IGG1-4 and C3d, the inflammation marker simultaneously for 176 foods, colorings, and additives. The ability to help reduce inflammation by personalizing a patient’s diet has the promise to reduce symptoms in cardiovascular, diabetes, IBS and other autoimmune diseases as well as the opportunity to aid in weight loss. The company has expanded the product range to include a FIT 22, FIT 132 and FIT 176 assays and recently launched Gut Barrier Panel.
The company has grown from 5 to just over 5,000 providers ordering the test in the USA and internationally through our distribution and Laboratory partners in Asia,Europe and Latin America. The company’s facilities include an ISO and FDA registered manufacturing facility, 2 CLIA High Complexity laboratories, Sales and Marketing and Logistic Capabilities. During the COVID Pandemic KBMO was one of the first commercial labs offering antibody testing and PCR testing to providers.